Advertisement
NVS vs PFE
Which Stock Would AI Choose? Novartis (NVS) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Novartis (NVS) has delivered stronger year-to-date and one-year returns compared to Pfizer (PFE), with NVS up approximately 16-17% YTD versus PFE’s near-flat performance.
- Both companies operate in the pharmaceutical sector but differ in scale, with Novartis maintaining a larger market capitalization and more consistent recent momentum.
- Recent pipeline developments include positive Phase 3 results for Pfizer’s LITFULO in vitiligo and priority review for a prostate cancer combination, while Novartis continues to benefit from oncology-focused innovation and regulatory wins.
- NVS exhibits lower volatility relative to broader market benchmarks, whereas PFE offers a higher dividend yield amid ongoing efforts to rebuild its pipeline post-patent expirations.
- Sector exposure remains similar for both, centered on innovative medicines, yet NVS has shown better relative positioning in recent market activity.
- Observable trends indicate NVS with more stable performance patterns in recent weeks, while PFE shows mixed sentiment tied to specific clinical updates.
Introduction
This comparison examines NVS and PFE, two established pharmaceutical companies, to highlight differences in recent performance, business drivers, and market positioning. The analysis focuses on verifiable developments over recent weeks and broader timeframes, providing context for traders and investors evaluating large-cap healthcare equities. It is relevant for those seeking insights into relative momentum, sector dynamics, and observable catalysts within the pharmaceutical industry.
Novartis Overview and Recent Performance
Novartis AG (NVS) is a global pharmaceutical company focused on innovative medicines in oncology, cardiology, and other therapeutic areas. In recent market activity, the stock has shown resilience, closing near $156.15 as of July 31, 2026, with year-to-date gains of approximately 16-17% and one-year returns exceeding 37%. Over the trailing 30 days and past quarter, performance reflected modest positive returns around 1-6.5%, supported by a strong innovation pipeline, regulatory advancements, and strategic moves in oncology. Sentiment in recent weeks has been influenced by consistent earnings beats and pipeline progress, contributing to relatively stable trading near moving averages.
Pfizer Overview and Recent Performance
Pfizer Inc. (PFE) is a major biopharmaceutical company with a broad portfolio spanning oncology, vaccines, and internal medicine. The stock closed at $25.01 on July 31, 2026, with year-to-date performance near flat to modestly positive and one-year returns around 5-6%. Recent weeks have featured mixed price behavior amid pipeline updates, including positive Phase 3 data for LITFULO in nonsegmental vitiligo and FDA priority review for a metastatic prostate cancer regimen. Broader influences include efforts to address patent expirations and advance new candidates in areas such as obesity and cancer, shaping sentiment in the current environment.
Trending AI Robots
Tickeron’s Trending AI Robots page at Trending AI Robots showcases a curated selection of AI trading bots designed for various market conditions. Tickeron offers hundreds of AI Trading Bots that trade thousands of different tickers, but only the best and most suitable for current market conditions earn placement in this section. Available bots feature diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, with historical statistics often spanning ranges such as win rates above 50% in optimized configurations and varying return profiles depending on market regimes. This resource allows users to explore automated approaches tailored to equities like those in healthcare. Review the full selection on the Trending AI Robots page for additional details.
Head-to-Head Comparison
Novartis (NVS) and Pfizer (PFE) both focus on pharmaceutical innovation but differ in business scale and recent momentum. NVS maintains a larger market capitalization and has demonstrated stronger relative performance in recent periods, with more consistent upward trajectory supported by oncology catalysts. PFE, while offering a higher dividend yield, faces greater near-term pressures from loss of exclusivity on key products and relies on a broader but rebuilding pipeline for future growth. Sector exposure is comparable, centered on high-value medicines, yet NVS shows lower beta characteristics and tighter trading ranges in recent market activity. Risk factors for PFE include patent cliffs and clinical trial variability, while NVS contends with competitive dynamics in its core areas. Market sentiment has favored NVS’s stability over PFE’s more event-driven updates in recent weeks.
Tickeron AI Verdict
Based on observable factors such as trend consistency, relative stability, and positioning amid recent developments, Tickeron’s AI would currently assign a higher probabilistic preference to NVS over PFE. This assessment draws from NVS’s stronger recent performance metrics and pipeline visibility compared to PFE’s mixed signals around patent impacts and selective catalysts. Outcomes remain subject to evolving market conditions and company-specific events.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVS is a StrongBuy and PFE is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NVS’s FA Score shows that 3 FA rating(s) are green whilePFE’s FA Score has 3 green FA rating(s).
- NVS’s FA Score: 3 green, 2 red.
- PFE’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVS’s TA Score shows that 2 TA indicator(s) are bullish while PFE’s TA Score has 5 bullish TA indicator(s).
- NVS’s TA Score: 2 bullish, 5 bearish.
- PFE’s TA Score: 5 bullish, 5 bearish.
Price Growth
NVS (@Pharmaceuticals: Major) experienced а -3.49% price change this week, while PFE (@Pharmaceuticals: Major) price change was +0.11% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.23%. For the same industry, the average monthly price growth was +0.30%, and the average quarterly price growth was +2.34%.
Reported Earning Dates
NVS is expected to report earnings on Oct 27, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.23% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| NVS | PFE | NVS / PFE | |
| Capitalization | 286B | 153B | 187% |
| EBITDA | 22.5B | 17.2B | 131% |
| Gain YTD | 12.744 | 13.144 | 97% |
| P/E Ratio | 22.79 | 35.25 | 65% |
| Revenue | 56.7B | 63.3B | 90% |
| Total Cash | 7.69B | N/A | - |
| Total Debt | 49B | 63.7B | 77% |
NVS | PFE | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 62 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 6 Undervalued | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 7 | 100 | |
SMR RATING 1..100 | 34 | 76 | |
PRICE GROWTH RATING 1..100 | 52 | 29 | |
P/E GROWTH RATING 1..100 | 26 | 7 | |
SEASONALITY SCORE 1..100 | n/a | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PFE's Valuation (3) in the Pharmaceuticals Major industry is in the same range as NVS (6). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
NVS's Profit vs Risk Rating (7) in the Pharmaceuticals Major industry is significantly better than the same rating for PFE (100). This means that NVS’s stock grew significantly faster than PFE’s over the last 12 months.
NVS's SMR Rating (34) in the Pharmaceuticals Major industry is somewhat better than the same rating for PFE (76). This means that NVS’s stock grew somewhat faster than PFE’s over the last 12 months.
PFE's Price Growth Rating (29) in the Pharmaceuticals Major industry is in the same range as NVS (52). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
PFE's P/E Growth Rating (7) in the Pharmaceuticals Major industry is in the same range as NVS (26). This means that PFE’s stock grew similarly to NVS’s over the last 12 months.
| NVS | PFE | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 65% |
| Stochastic ODDS (%) | 2 days ago 49% | 2 days ago 63% |
| Momentum ODDS (%) | 2 days ago 51% | 2 days ago 50% |
| MACD ODDS (%) | 2 days ago 43% | N/A |
| TrendWeek ODDS (%) | 2 days ago 43% | 2 days ago 52% |
| TrendMonth ODDS (%) | 2 days ago 50% | 2 days ago 48% |
| Advances ODDS (%) | 19 days ago 52% | 9 days ago 52% |
| Declines ODDS (%) | 2 days ago 44% | 4 days ago 58% |
| BollingerBands ODDS (%) | 2 days ago 32% | 2 days ago 57% |
| Aroon ODDS (%) | N/A | 2 days ago 45% |
Advertisement
NVS and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVS has been loosely correlated with GSK. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if NVS jumps, then GSK could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.04% | ||
| BMY - PFE | 57% Loosely correlated | -1.27% | ||
| MRK - PFE | 55% Loosely correlated | +0.21% | ||
| AMGN - PFE | 53% Loosely correlated | -0.63% | ||
| NVS - PFE | 51% Loosely correlated | -0.55% | ||
| BIIB - PFE | 51% Loosely correlated | -0.39% | ||
More | ||||